OptimizeRx
OPRX
51 hedge funds and large institutions have $72.4M invested in OptimizeRx in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
4.35% less ownership
Funds ownership: 58.96% → 54.62% (-4.3%)
9% less funds holding
Funds holding: 56 → 51 (-5)
16% less capital invested
Capital invested by funds: $85.8M → $72.4M (-$13.4M)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.5M
Top Buyers
Top Sellers
OPRX Hedge Fund Activity: Q1 2020 in Review
51 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q1 2020, worth a combined $72.4M — down 16% from $85.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of OPRX and 8 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was G2 Investment Partners Management, adding an estimated $1.54M. The largest seller was Wolverine Asset Management, cutting an estimated $2.67M.
- 51 institutional investors held OptimizeRx (OPRX) as of Q1 2020, down from 56 in Q4 2019.
- Funds reported $72.4M of OptimizeRx stock for Q1 2020, down 16% quarter-over-quarter.
- 8 funds opened new OptimizeRx positions in Q1 2020 and 12 closed out, a net change of -4 holders.
- The largest OptimizeRx buyer in Q1 2020 was G2 Investment Partners Management, an estimated $1.54M added.
- The largest OptimizeRx seller in Q1 2020 was Wolverine Asset Management, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2020.